BMO Capital Thinks Checkmate Pharmaceuticals’ Stock is Going to Recover

In a report released today, Do Kim from BMO Capital maintained a Buy rating on Checkmate Pharmaceuticals (CMPIResearch Report), with a price target of $32.00. The company’s shares closed last Tuesday at $6.27, close to its 52-week low of $5.84.

According to, Kim is a 5-star analyst with an average return of 19.2% and a 52.0% success rate. Kim covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Vertex Pharmaceuticals, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Checkmate Pharmaceuticals with a $26.67 average price target, a 328.8% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $29.00 price target.

See today’s analyst top recommended stocks >>

Checkmate Pharmaceuticals’ market cap is currently $140.1M and has a P/E ratio of -8.00. The company has a Price to Book ratio of 1.22.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CMPI in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Checkmate Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing its proprietary technology to harness the power of the immune system to combat cancer.